Chapter 15
The Coagulopathy of Chronic Liver Disease. Is the Long and Widely Held Belief Being Dispelled?
Armando Tripodi PhD,
Armando Tripodi PhD
Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Internal Medicine, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, and University of Milan, Italy
Search for more papers by this authorArmando Tripodi PhD,
Armando Tripodi PhD
Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Department of Internal Medicine, IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, and University of Milan, Italy
Search for more papers by this authorBook Editor(s):Roberto de Franchis MD, AGAF,
Roberto de Franchis MD, AGAF
Professor of Gastroenterology Head
Department of Medical Sciences, University of Milan, and Gastroenterology 3 Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico Mangiagalli and Regina Elena Foundation, Milan, Italy
Search for more papers by this authorFirst published: 17 November 2010
Summary
This chapter contains sections titled:
-
Introduction
-
How the dogma was born and how it is challenged
-
Hyper-rather than hypocoagulability seems to be the distinctive feature of chronic liver disease
-
Concluding remarks
-
References
References
- Hedner U, Erhardtsen E (2003) Hemostatic disorders in liver disease. In: Schiff ER, Sorrell MF, Maddrey WC (eds) Schiff's Diseases of the Liver. Lippincott Williams & Wilkins: Philadelphia, pp. 625–36.
- Bosch J, Thabut D, Bendtsen F, et al. (2004) for the European Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 127: 1123–30.
- Bosch J, Thabut D, Albillos A, et al. (2008) for the International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology 47: 1604–14.
- Lodge JP, Jonas S, Jones RM, et al. (2005) for the rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 11: 973–9.
- Planinsic RM, van der Meer J, Testa G, et al. (2005) Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 11: 895–900.
- Tripodi A, Salerno F, Chantarangkul V, et al. (2005) Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 41: 553–8.
- Tripodi A, Primignani M, Chantarangkul V, et al. (2006) Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 44: 440–5.
- Caldwell SH, Hoffman M, Lisman T, et al. (2006) Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 44: 1039–46.
- Tripodi A, Caldwell SH, Hoffman M, et al. (2007) The prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 26: 141–8.
- Tripodi A, Chantarangkul V, Mannucci PM (2009) Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. Br J Haematol 147: 77–82.
- Dahlback B (2004) Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 79: 109–16.
- Tripodi A, Primignani M, Chantarangkul V, et al. (2009) An imbalance of provs. anticoagulation factors in plasma from patients with cirrhosis. Gastroenterology 137: 2105–11.
- Tripodi A, Primignani M, Lemma L, et al. (2010) Detection of the imbalance of pro- vs. anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 52: 248–55.
- Northup PG, McMahon MM, Ruhl AP, et al. (2006) Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 101: 1524–8.
- Søgaard KK, Horváth-Puhó E, Grønbaek H, et al. (2009) Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 104: 96–101.
- Lisman T, Bakhtiari K, Pereboom IT, et al. (2010) Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. JHepatol 52: 355–61.
- Valla DC (2008) Thrombosis and anticoagulation in liver disease. Hepatology 47: 1384–93.
- Okuda K, Ohnishi K, Kimura K, et al. (1985) Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 89: 279–86.
- Francoz C, Belghiti J, Vilgrain V, et al. (2005) Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 54: 691–7.
- Bauer KA (2006) New anticoagulants. Hematology. Am Soc Hematol Educ Program: 450–6.
-
Tripodi A (2009) Monitoring oral anticoagulant therapy. In: Kitchen S, Olson JD, Preston FE (eds) Quality in Laboratory Hemostasis and Thrombosis. Wiley-Blackwell: Oxford, pp. 179–89.
10.1002/9781444303575.ch18 Google Scholar
- Lisman T, Bongers TN, Adelmeijer J, et al. (2006) Elevated levels of von Wille-brand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 44: 53–61.
- Rockey DC, Caldwell SH, Goodman ZD, et al. (2009) American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 49: 1017–44.
